

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/935,557	08/22/2001	. Erik Gunther	GUNE117293	8854
26389 7590 03/26/2007 CHRISTENSEN, O'CONNOR, JOHNSON, KINDNESS, PLLC 1420 FIFTH AVENUE SUITE 2800 SEATTLE, WA 98101-2347			EXAMINER	
			CLOW, LORI A	
			ART UNIT	PAPER NUMBER
•		1631		
SHORTENED STATUTOR	Y PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE	
3 MONTHS		03/26/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

	Application No.	Applicant(s)				
	09/935,557	GUNTHER, ERIK				
Office Action Summary	Examiner	Art Unit				
•	Lori A. Clow, Ph.D.	1631				
The MAILING DATE of this communication app						
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be time 17 iii apply and will expire SIX (6) MONTHS from the cause the application to become ABANDONE	N. nely filed - the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1)⊠ Responsive to communication(s) filed on 29 De	ecember 2006					
	action is non-final.					
·—	<u> </u>					
closed in accordance with the practice under E						
Disposition of Claims						
4) Claim(s) <u>1-4,6-25 and 32-43</u> is/are pending in t	he application.					
4a) Of the above claim(s) is/are withdrawn from consideration.						
5)⊠ Claim(s) <u>1,6-8,10,16,19-21,23,24,32,35 and 37-43</u> is/are allowed.						
6)⊠ Claim(s) <u>2, 3, 4, 9, 11-15, 17, 18, 22, 25, 33, 34, and 36</u> is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or	election requirement.					
Application Papers						
9) The specification is objected to by the Examine	г.					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the						
Replacement drawing sheet(s) including the correcti						
11)☐ The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
12) ☐ Acknowledgment is made of a claim for foreign a) ☐ All b) ☐ Some * c) ☐ None of:)-(d) or (f).				
1. Certified copies of the priority documents have been received.						
 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage 						
application from the International Bureau		od III dilo Nadonal Glago				
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)						
1) Notice of References Cited (PTO-892)	4) X Interview Summary	(PTO-413)				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08)	Paper No(s)/Mail Da 5) Notice of Informal P					
Paper No(s)/Mail Date 6) Other:						
		·				

Application/Control Number: 09/935,557

Art Unit: 1631

DETAILED ACTION

Applicants' arguments, filed 29 December 2006, have been fully considered. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application.

Claims 1-4, 6-25, 32-43 are currently pending. Claims 5 and 26-31 have been cancelled. Claims 1 and 32 are allowable. Claims 12-17 and 22-25, previously withdrawn from consideration as a result of a restriction requirement, require all the limitations of an allowable claim. Pursuant to the procedures set forth in MPEP § 821.04(a), the restriction requirement among species of claims 12-17 and 22-25, as set forth in the Office action mailed on 22 September 2003, is hereby withdrawn and claims 12-17 and 22-25 are hereby rejoined and fully examined for patentability under 37 CFR 1.104. In view of the withdrawal of the restriction requirement, applicant(s) are advised that if any claim presented in a continuation or divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once the restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See *In re Ziegler*, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Application/Control Number: 09/935,557

Art Unit: 1631

Claims 2, 3, 4, 9, 11-15, 17, 18, 22, 25, 33, 34, and 36 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 2 recites, "profile to identify the one or more analytes". It is unclear what analytes are intended. Are they the analytes possessing pharmacological activity or some other analyte? Clarification through clearer claim language is requested.

Claims 3 and 33 recite, "identification comprises classifying all the expression profiles". It is unclear as to what the steps of identification are limiting". Is this the identification of analytes possessing pharmacological activity? Clarification is requested.

Claims 4, 9, 11, 15, 17, 18, 22, 25, 34, and 36 recite, "wherein any of the steps used to perform at least one of the assays comprises". This is unclear, as there are no steps recited in which to perform assays. Perhaps applicant intends that claims to read, "wherein any of the assays are performed using". Clarification is requested.

Conclusion

Claims 1, 6, 7, 8, 10, 16, 19, 20, 21, 23, 24, 32, 35, and 37-43 are allowable. Claims 1 and 32 are allowable, as the prior art does not teach or fairly suggest comparing a third expression profile with a first and second expression profile to identify analytes that induce the third expression profile that is more similar to the first than the second expression profile and wherein the analytes identified as inducing the third expression profile are indicative of the those possessing pharmacological activity.

Art Unit: 1631

Inquiries

Papers related to this application may be submitted to Technical Center 1600 by facsimile transmission. Papers should be faxed to Technical Center 1600 via the PTO Fax Center. The faxing of such papers must conform with the notices published in the Official Gazette, 1096 OG 30 (November 15, 1988), 1156 OG 61 (November 16, 1993), and 1157 OG 94 (December 28, 1993) (See 37 CFR § 1.6(d)). The Central Fax Center Number is (571) 273-8300.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Lori A. Clow, Ph.D., whose telephone number is (571) 272-0715. The examiner can normally be reached on Monday-Friday from 10 am to 6:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Irem Yucel can be reached on (571) 272-0781.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

March 15, 2007 Lori A. Clow, Ph.D.

Art Uniț 1631

Low of Class

3/15/97